Practical oncology,
Journal Year:
2022,
Volume and Issue:
23(4), P. 211 - 224
Published: Dec. 25, 2022
Liquid
biopsy
is
the
analysis
of
tumor
fragments
(entire
cells,
nucleic
acids,proteins)
in
hysiological
and
pathological
body
liquids.
This
technology
has
already
been
included
standard
procedures
detecting
secondary
mutations,
which
are
associate
with
acquired
drug
resistance.
a
promising
tool
for
early
cancer
detection,
evaluation
success
radical
surgery,
monitoring
residual
disease,
assessment
treatment
efficacy
etc.
JAMA Otolaryngology–Head & Neck Surgery,
Journal Year:
2024,
Volume and Issue:
150(7), P. 580 - 580
Published: May 23, 2024
Circulating
tumor
human
papillomavirus
DNA
(ctHPV
DNA)
has
shown
potential
as
a
biomarker
capable
of
improving
outcomes
in
patients
with
HPV-related
oropharyngeal
(OP)
cancer.
It
can
be
isolated
from
plasma
or
saliva,
the
latter
offering
reduced
invasiveness
and
theoretic
reduction
lead
time.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(20), P. 3474 - 3474
Published: Oct. 14, 2024
This
review
article
aims
to
summarize
broadly
recent
developments
in
the
treatment
of
HPV-associated
cancers,
including
cervical
cancer
and
head
neck
squamous
cell
carcinoma.
Relatively
new
treatments
targeting
key
HPV
E6
E7
oncoproteins,
gene
editing
with
TALENs
CRISPR/Cas9,
are
discussed.
Given
increased
immunogenicity
HPV-related
diseases,
other
therapies
such
as
PRR
agonists,
adoptive
transfer,
tumor
vaccines
reaching
clinical
trial
phase.
Due
mechanism,
immunogenicity,
reversibility
carcinogenesis,
cancers
present
unique
targets
for
current
future
therapies.
Pathogens,
Journal Year:
2023,
Volume and Issue:
12(7), P. 908 - 908
Published: July 5, 2023
Human
papillomavirus
(HPV)
is
recognized
as
being
related
to
a
wide
variety
of
known
cancers:
cervical,
oropharyngeal,
anal,
vaginal,
penile,
and
skin.
For
some
these
cancers,
rigorous
algorithms
for
screening,
therapeutical
interventions,
follow-up
procedures
have
been
established.
Vaccination
using
the
nonvalent
anti-HPV
vaccine,
which
prevents
infection
regarding
most
frequently
involved
high-risk
HPV
types
(16,
18,
31,
33,
45,
52,
58)
low-risk
(6
11),
has
also
extensively
prevented,
controlled,
even
eradicated
infections.
Still,
with
all
multidisciplinary
burden
cancers
still
high
worldwide.
The
circulating
DNA
HPV-induced
thought
be
an
adequate
biomarker
optimizing
control
virus-related
cancers.
We
analyzed
literature
published
in
last
5
years
ctDNA
four
above-mentioned
used
assay
detection
was
droplet
digital
PCR
assay,
management
therapy
late
stages
cancer.
could
not
early
any
studied
OPSCCs
were
frequent
via
assays.
Larger,
properly
designed
cohort
studies
might
establish
clinical
utility
this
biomarker.
Cancer Cell International,
Journal Year:
2023,
Volume and Issue:
23(1)
Published: Dec. 18, 2023
Abstract
Cervical
cancer
is
a
leading
cause
of
gynecological
death
in
the
world.
Human
papillomavirus
(HPV)
most
causative
factor
cervical
cancer.
In
addition,
many
genetic
factors
are
involved
development.
Most
studies
focus
on
samples
to
do
research
work
about
and
precancerous
lesions,
but
no
sensitive
or
specific
biomarkers
were
found.
High-throughput
genomic
technologies
able
capture
information
from
tumors
lesions
blood,
thus
providing
new
way
for
early
diagnosis
precancer
Blood
an
ideal
specimen
detecting
because
it
contains
lot
information,
such
as
circulating
tumor
cells
DNA
(ctDNA).
This
article
reviews
clinical
use
challenges
blood
ctDNA
testing
patients
with
ChemMedChem,
Journal Year:
2024,
Volume and Issue:
19(16)
Published: May 13, 2024
Cervical
cancer
seriously
affects
the
health
of
women
worldwide.
Persistent
infection
high-risk
HPV
(Human
Papilloma
Virus)
can
lead
to
cervical
cancer.
There
is
a
great
need
for
timely
and
efficient
screening
methods
The
current
are
mainly
based
on
cytology
testing.
made
Pap
smear
liquid-based
cytology,
while
testing
immunological
nucleic
acid
level
detection
methods.
This
review
introduces
human
papillomavirus
in
detail.
advantages
limitations
also
summarized
compared.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 30, 2024
ABSTRACT
Purpose
The
human
papillomavirus
(HPV)
is
a
significant
cause
of
cervical
cancer.
We
hypothesized
that
detecting
viral
cell-free
HPV
DNA
(cfDNA)
before,
during,
and
after
chemoradiation
(chemoRT)
could
provide
insights
into
disease
extent,
clinical
staging,
treatment
response.
Experimental
Design
Sixty-six
patients
with
locally
advanced
cancer
were
enrolled
between
2017
2023,
49
receiving
standard-of-care
(SOC)
17
participating
in
trial
combining
therapeutic
vaccine
(PDS0101;
IMMUNOCERV).
Plasma
samples
collected
at
baseline,
during
weeks
1,
3,
5
chemoRT,
3-4
months
chemoRT.
cfDNA
was
quantified
using
droplet
digital
PCR
targeting
the
E6/E7
oncogenes
13
high-risk
types.
MRI
performed
baseline
before
brachytherapy.
Results
median
follow-up
23
months,
recurrence-free
survival
(RFS)
78.4%
2
years.
Baseline
nodal
extent
correlated
levels.
levels
peaked
week
1
radiation
decreased
through
treatment.
Patients
PDS0101
had
higher
rate
undetectable
type
16
compared
to
SOC.
clearance
better
2-yr
RFS
(92.9%
vs.
30%,
log-rank
p=0.0067).
strongest
predictor
achieving
concordance
index
(CI)
0.83,
which
improved
when
combined
response
(CI
0.88).
Conclusions
change
dynamically
first
predict
RFS,
linked
rapid
decline.
Monitoring
chemoRT
may
guide
tailoring
personalized
Practical oncology,
Journal Year:
2022,
Volume and Issue:
23(4), P. 211 - 224
Published: Dec. 25, 2022
Liquid
biopsy
is
the
analysis
of
tumor
fragments
(entire
cells,
nucleic
acids,proteins)
in
hysiological
and
pathological
body
liquids.
This
technology
has
already
been
included
standard
procedures
detecting
secondary
mutations,
which
are
associate
with
acquired
drug
resistance.
a
promising
tool
for
early
cancer
detection,
evaluation
success
radical
surgery,
monitoring
residual
disease,
assessment
treatment
efficacy
etc.
